Clay B. Siegall, Ph.D.
President, Chief Executive Officer and Chairman of the Board
Clay B. Siegall, Ph.D., co-founded Seattle Genetics in 1998 and is the company's President, Chief Executive Officer and Chairman of the Board. A scientist by training with an emphasis on targeted cancer therapies, Dr. Siegall built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in developing antibody-drug conjugates (ADCs) and in securing the 2011 FDA approval of its first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is commercially available in 50 countries. Seattle Genetics is also advancing a diverse pipeline of proprietary ADCs for the treatment of cancer.
Under Dr. Siegall’s leadership, Seattle Genetics has entered into multiple strategic licenses for its ADC technology, including with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, that have generated more than $300 million to date. Across internal and collaborator programs, there are more than 20 ADCs in clinical development using Seattle Genetics’ technology. Dr. Siegall has also led Seattle Genetics’ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001.
Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Boards of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, Mirna Therapeutics and Washington Roundtable. Dr. Siegall has been the recipient of a number of awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences, and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. He is an author on more than 70 publications and holds 15 patents. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.